Small Intestine News and Research

RSS

Researchers find new fusion protein for E.coli bacterium vaccine development

South Dakota State University research is exploring a "fusion strategy" for making improved vaccines to protect pigs and humans against some strains of E. coli.

2 Sep 2010

Reactivation of CDX2 gene may halt progression of colon cancer

The intestines have to work properly if we are to benefit from the food we eat. Digestive juices must be secreted, the food broken down into smaller components and then transported through the gut wall and onwards to muscles and organs. The lining of the gut is coated in epithelial cells, a specialised layer that produces mucous and hormones while keeping dangerous bacteria and toxins at bay. Close contact with pathogenic microbes and toxins means that the epithelial cells may mutate to form cancer.

30 Aug 2010

First ROSE procedures with USGI Medical's Incisionless Operating Platform performed in Europe

USGI Medical, Inc., the Incisionless Surgery Company, announced that a surgeon in the U.K. successfully completed Europe's first two scar-free stomach surgery repairs using the company's Incisionless Operating Platform™ (IOP). Elemental Healthcare Ltd. distributes the IOP in the U.K. market.

30 Aug 2010

Scientists discover synergistic effect to delay fat digestion

Institute of Food Research scientists have discovered an unexpected synergy that helps break down fat. The discovery provides a focus to find ways to slow down fat digestion, and ultimately to create food structures that induce satiety.

19 Aug 2010

Cancer survivor to celebrate 100th birthday

Loyola University Hospital cancer patient Mary Cipolla was 89 years old when she underwent one of the most extensive operations in surgery, known as the Whipple procedure.

28 Jul 2010

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.

23 Jul 2010

New & improved rotavirus vaccine to be trialed in Melbourne

Now a vaccine is being developed against rotavirus in Melbourne. At present Australian children were given rotavirus vaccine at the age of six to eight weeks since 2007. This new vaccine will be applicable to infants from birth.

20 Jul 2010

Encap Drug Delivery granted patents in US, Europe for DuoCap capsule delivery system

Encap Drug Delivery, a leading provider of development and manufacturing services to the pharmaceutical industry, has received confirmation that their DuoCap™, capsule delivery system has been granted patents for US and Europe.

13 Jul 2010

Researchers show unexpected, physiological effects of water

Name a drink that can make you more alert for late-night studying, prevent you from fainting after giving blood, and even promote a teensy bit of weight loss. Chances are you didn't say water. But that's the right answer.

7 Jul 2010

First Australian intestinal transplant

Mr. Brendan Cole, 32 became the first recipient of a successful intestinal transplant in Australia. Last Friday he had his intestines and organs removed from his abdomen that followed a 12 hour operation at Austin Health.

4 Jul 2010

FDA grants orphan drug designation for Chiasma's Octreolin

Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.

28 Jun 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Gastric bypass surgery improves Type 2 diabetes by other mechanisms in addition to weight loss and does so better than a low-calorie diet despite achieving equal weight loss, a new study finds. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010

Low LDL cholesterol levels increase life expectancy

A University of Minnesota study definitively shows that those with decreased LDL cholesterol levels can count on an increased life expectancy. The research is published in the May 24 edition of the Annals of Surgery.

8 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Here's another reason to breast feed your baby: Canadian researchers have discovered how a probiotic found in breast milk reduces or eliminates painful cramping in the gut. In a new research report published online in the FASEB Journal, these scientists use mice to show that a specific strain of Lactobacillus reuteri decreases the force of muscle contractions in the gut within minutes of exposure.

3 Jun 2010

$FDA warns on possible fracture risk with proton pump inhibitors use$

FDA warns on possible fracture risk with proton pump inhibitors use

The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk.

26 May 2010

Researchers study correlation between type 2 diabetes and increased risk of cancer

Cancer and diabetes - are risk factors the same for these two diseases? Or does diabetes cause processes in the body which promote the onset or growth of cancer? It is still unclear why diabetics have a higher rate of cancer than people who are not affected by this metabolic disorder.

21 May 2010